Innovation agency

UAB "SynHet" implements the project "Development of innovative safe production of isocyanate" no. 02-020-K-0063. The total value of the project is EUR 260,806.92, of which EUR 160,568.21 is from the European Regional Development Fund.

The project is implemented in accordance with the Agreement, development program progress measure No. 05-001-01-05-07 "Create a coherent system for the promotion of innovative activities" the effects of the activity "Promote the supply of innovations" "Invest in the development of new products and provide opportunities for researchers to participate in R&D activities of companies, promote intellectual property, early testing of new products created production, preparation for the market" (Central and Western Lithuania region) in the description of project financing conditions, approved by the Minister of Economy and Innovation of the Republic of Lithuania in 2023. July 7 by order no. 4-368, in the project administration and financing rules, approved by the Minister of Finance of the Republic of Lithuania in 2022. June 22 by order no. 1K-237 "On the implementation of the 2021-2027 European Union Funds Investment Program and the Economic Revitalization and Resilience Enhancement Plan "New Generation Lithuania", and the conditions and procedures set forth in the legal acts of the EU and the Republic of Lithuania referred to in them.

UAB SynHet company was established in 2017. Since its establishment, the company has been conducting the synthesis of organic compounds as well as biologically active molecules for the pharma and biotechnology companies. Medical device manufacturers, as with active pharmaceutical ingredients, must use raw materials of high purity in their manufacturing processes. These requirements are set by the European Medicines Agency (or, in the case of the US, the Food and Drug Administration FDA), where any compounds that are used as active ingredients (and for their production) or enter the human body are regulated by legislation. Isocyanates are one of the most active classes of organic compounds and are highly reactive, making them very difficult to obtain chemically pure. UAB SynHet has developed a method for high-purity target DIP in small quantities. Thus, in the frame of the “Inobranda” grant application, further innovation is based on developing upscale processes using continuous flow chemistry. DIP and other isocyanates are of particular importance to drug/medical device manufacturers and will be commercialized after successful “Inobranda” project completion.